Cash Earnings per Share

(redirected from Cash EPS)

Cash Earnings per Share

A measure of a publicly-traded company's cash on hand, calculated by dividing the company's cash flow by the number of shares outstanding. Cash earnings per share helps determine a company's ability to service debt, pay dividends and perform other transactions. A high cash earnings per share, coupled with a low share price, indicates that the company likely has strong earnings and that the share price will soon rise. It is also called cash flow per share.
References in periodicals archive ?
Bank of Nova Scotia, also known as Scotiabank, reported an adjusted cash EPS of $1.88 in the quarter which beat expectations of $1.83 per share.
GAAP and Cash EPS accretion per BB and T share in 2021 is expected to be approximately 13% and 17%, respectively (based on Street estimates).
Valeant's managers asked the investment community to ignore the GAAP numbers and concentrate on "cash eps," a metric of their own invention.
GAAP and Cash EPS accretion per BB&T share in 2021 is expected to be approximately 13% and 17%, respectively .
It is complementary to our recent acquisition of Trafficware, both of which are cash EPS accretive in first full year of operations, said Bradley H.
Based on its 2016 revenue guidance, the company expects 2016 adjusted diluted cash EPS to range between $1.85 and $1.95.
"We expect considerable operating synergies resulting in sustained profitable growth, as well as double-digit adjusted cash EPS (earnings-per-share) growth," said Michael Dinkins, executive vice president and chief financial officer of Greatbatch.
"We reiterate our 'Outperform' rating for CVS Health, based on the continuation of strong operating momentum, our belief that the integrated model is favorably positioned in the marketplace, and reasonable valuation at 16.9 times our 2015 adjusted cash EPS estimate," he wrote in a recent research note.
Cash EPS (see Non-GAAP Financial Information below) was USD0.84 for the fiscal year 2012, an increase of 62%, from the USD0.52 for the same period in fiscal year 2011.
With strong third quarter performance, we are raising our fourth quarter Cash EPS guidance to $0.80 to $0.95, which does not include the potential milestone of $45 million from GlaxoSmithKline that is now scheduled to occur in the first quarter of 2012.'
Cash EPS for FY11stands at ' 5.45 per share against ' 4.18 per share in FY10.
The company also projects to record adjusted cash EPS of between USD3.85 and USD4.15, and adjusted EBITDA of between USD925m and USD1bn.